STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration ...
STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.
CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects. Utilizing this system, ...
A Northwestern Medicine study published in the Journal of Clinical Investigation has uncovered a connection between a well-known cancer-related protein and a major RNA modification process, which may ...
University of Chicago researchers have developed a liquid biopsy test based on modification patterns in microbiome-derived cell-free RNA that predicts colorectal cancer (CRC) with greater accuracy ...
A new liquid biopsy developed by researchers at the University of Chicago is offering a powerful new window into cancer’s earliest stages by flagging subtle shifts in the gut microbiome. Unlike ...
This study is led by Professor XiaoqinLiu (Peking University Institute of Advanced Agricultural Sciences, Shandong Laboratory of Advanced Agriculture Sciences, Shangdong, China). The authors explored ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback